These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28918311)

  • 1. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
    Williams E; Bullock AN
    Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
    Engers DW; Frist AY; Lindsley CW; Hong CC; Hopkins CR
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3248-52. PubMed ID: 23639540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
    Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
    ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMP type I receptor inhibition reduces heterotopic [corrected] ossification.
    Yu PB; Deng DY; Lai CS; Hong CC; Cuny GD; Bouxsein ML; Hong DW; McManus PM; Katagiri T; Sachidanandan C; Kamiya N; Fukuda T; Mishina Y; Peterson RT; Bloch KD
    Nat Med; 2008 Dec; 14(12):1363-9. PubMed ID: 19029982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
    Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
    J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
    J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
    Davis AJ; Brooijmans N; Brubaker JD; Stevison F; LaBranche TP; Albayya F; Fleming P; Hodous BL; Kim JL; Kim S; Lobbardi R; Palmer M; Sheets MP; Vassiliadis J; Wang R; Williams BD; Wilson D; Xu L; Zhu XJ; Bouchard K; Hunter JW; Graul C; Greenblatt E; Hussein A; Lyon M; Russo J; Stewart R; Dorsch M; Guzi TJ; Kadambi V; Lengauer C; Garner AP
    Sci Transl Med; 2024 May; 16(749):eabp8334. PubMed ID: 38809966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
    Luo Y; Alsamarah A; Zhang K; Hao J
    Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
    Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K
    Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
    Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
    Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva.
    Ullrich T; Arista L; Weiler S; Teixeira-Fouchard S; Broennimann V; Stiefl N; Head V; Kramer I; Guth S
    Bioorg Med Chem Lett; 2022 May; 64():128667. PubMed ID: 35276359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.
    Fukuda T; Kohda M; Kanomata K; Nojima J; Nakamura A; Kamizono J; Noguchi Y; Iwakiri K; Kondo T; Kurose J; Endo K; Awakura T; Fukushi J; Nakashima Y; Chiyonobu T; Kawara A; Nishida Y; Wada I; Akita M; Komori T; Nakayama K; Nanba A; Maruki Y; Yoda T; Tomoda H; Yu PB; Shore EM; Kaplan FS; Miyazono K; Matsuoka M; Ikebuchi K; Ohtake A; Oda H; Jimi E; Owan I; Okazaki Y; Katagiri T
    J Biol Chem; 2009 Mar; 284(11):7149-56. PubMed ID: 18684712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
    Yamamoto H; Sakai N; Ohte S; Sato T; Sekimata K; Matsumoto T; Nakamura K; Watanabe H; Mishima-Tsumagari C; Tanaka A; Hashizume Y; Honma T; Katagiri T; Miyazono K; Tomoda H; Shirouzu M; Koyama H
    Bioorg Med Chem Lett; 2021 Apr; 38():127858. PubMed ID: 33609658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
    Kaplan FS; Seemann P; Haupt J; Xu M; Lounev VY; Mullins M; Shore EM
    Methods Enzymol; 2010; 484():357-73. PubMed ID: 21036241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
    Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
    Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
    Mucha BE; Hashiguchi M; Zinski J; Shore EM; Mullins MC
    Bone; 2018 Apr; 109():225-231. PubMed ID: 29307777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.